Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06518551 · ClinicalTrials.gov registry record · Phase 1

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

A Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Omar Nadeem, MD.

Recruiting
Registry status
Phase 1
Development phase
49
Enrollment target
3
Study locations

NCT06518551 is a Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma that is actively recruiting participants, run by Omar Nadeem, MD. The registered enrollment target is 49 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06518551, a Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Omar Nadeem, MD.

RECRUITING
Registry status
Phase 1
Development phase
49 participants
Enrollment target
3
Study locations

Study Summary

The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)

Conditions Studied

Multiple Myeloma Refractory Multiple Myeloma Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Iberdomide
  • DRUG Elotuzumab

Study Locations (3)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2024-11-01
Est. Completion 2034-12-31
Phase Phase 1

Sponsor

Omar Nadeem, MD

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06518551

The ClinicalTrials.gov registry entry for NCT06518551 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower). The listed sponsor is Omar Nadeem, MD, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT06518551 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06518551 about?

NCT06518551 is a clinical study titled "Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM". The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) ...

What is the current status of trial NCT06518551?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2024-11-01. Estimated completion is 2034-12-31.

What conditions does trial NCT06518551 study?

This clinical trial studies the following conditions: Multiple Myeloma, Refractory Multiple Myeloma, Myeloma.

What interventions are being tested in trial NCT06518551?

The interventions under investigation include: Dexamethasone (DRUG), Iberdomide (DRUG), Elotuzumab (DRUG).

Who is sponsoring clinical trial NCT06518551?

This trial is sponsored by Omar Nadeem, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06518551 being conducted?

This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Refractory Multiple Myeloma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.